Trial Profile
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 24 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 24 May 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 03 Dec 2021 Planned End Date changed from 31 Dec 2020 to 1 Dec 2022.